Brain Stimulation for Opioid Use Disorder
Trial Summary
What is the purpose of this trial?
Investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. In Phase I, the EEG provided validation of expected changes in these networks following tDCS stimulation of the DLPFC. In this current phase (II), the investigators will perform a larger randomized clinical trial (RCT) (active vs. sham control) to address long-term neurobehavioral outcomes, including opioid relapse, craving, and sustained EEG changes.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it requires recent initiation of buprenorphine or methadone, so you may need to continue these medications during the trial.
What data supports the effectiveness of this treatment for opioid use disorder?
Is transcranial direct current stimulation (tDCS) safe for humans?
How is transcranial direct current stimulation (tDCS) unique in treating opioid use disorder?
Transcranial direct current stimulation (tDCS) is unique because it uses a non-invasive method to deliver a small electrical current to specific brain areas, which can help reduce cravings and improve decision-making and cognitive functions in people with opioid use disorder. Unlike traditional drug treatments, tDCS directly targets brain activity and can be combined with cognitive training to enhance its effects.12569
Research Team
Abrantes Abrantes, Ph.D.
Principal Investigator
Butler Hospital
Michael Stein, M.D.
Principal Investigator
Boston University
Eligibility Criteria
This trial is for individuals with Opioid Use Disorder. Participants should have a history of opioid dependency but are currently seeking treatment. The study excludes those who might have other medical conditions that could interfere with the trial or pose risks.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive five sessions of tDCS+CCN priming stimulation or sham tDCS+CCN priming over consecutive business days
Maintenance Treatment
Participants continue buprenorphine or methadone maintenance treatment while being monitored for opioid relapse and craving
Follow-up
Participants are monitored for long-term neurobehavioral outcomes, including opioid relapse and craving
Treatment Details
Interventions
- tDCS (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Butler Hospital
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator